Trodelvy® (sacituzumab govitecan-hziy) is an advanced therapy used for certain metastatic breast cancers, including triple-negative and HR-positive/HER2-negative cases. However, Trodelvy in India is not yet commercially approved and is not available through standard hospital or pharmacy channels.
Despite this, patients in India can still access the medicine through regulated pathways such as the Named Patient Program (NPP). Under this process, doctors can prescribe the medicine, and it can be imported from countries where it is approved.
Indian Pharma Network supports patients and healthcare providers in accessing such therapies through compliant sourcing and logistics.
For assistance, WhatsApp: +91 98104 69557 or call Toll-Free: 1800 1200 365.